November 13, 2009
Inostics acquires from Johns Hopkins University an exclusive license for detection of PIK3CA
Subsidiary of Indivumed aims to develop DNA-based blood tests for individualizing cancer therapy
Hamburg and Washington (DC), November 13, 2009 – Inostics GmbH, a molecular diagnostics company providing molecular tools and services to support individualized cancer patient management and drug development, today announced it has obtained a world-wide exclusive license for detection of PIK3CA mutations from [...]
October 2, 2009
Indivumed expands collaboration with Georgetown University
Personalized Therapies for Cancer Patients
Hamburg/Washington DC (USA): Indivumed GmbH, a Hamburg-based company specialized in the analysis and procurement of highly standardized tissue samples and data of tumor patients, for the first time participates in clinical research projects exploring personalized therapies for cancer patients. The trials will be conducted at the newly founded Otto J. Ruesch Center for the Cure [...]
September 23, 2009
ECCO 15-ESMO 34 Cancer Congress Introduces Indivumed’s New Cancer Drug Test Platform
Hamburg/Berlin: Europe’s largest cancer congress ECCO 15-ESMO 34 has introduced today an innovative test platform for the evaluation of novel cancer drug candidates.* The test has been developed by Hamburg-based Indivumed GmbH, a company specialized on the analysis and procurement of highly standardized tissue samples and data of tumor patients. The test is available for [...]
April 27th, 2009
Indivumed – Ventana Cancer Research Symposium
International experts in Hamburg to improve cancer therapy
Hamburg, April 27th-28th, 2009
Leading experts from the National Cancer Institute (NCI) in the US, the pharmaceutical industry and academic centers met in Hamburg April 27th- 28th, 2009 to discuss the most promising developments in molecular diagnostics and their role in furthering individualized cancer therapies.
The [...]
March 29, 2009
Indivumed founds new biotech company with leading US scientists from The Johns Hopkins University
Hamburg, Germany
The world’s most well-known cancer researcher, Prof. Bert Vogelstein, celebrated the founding of the unique biotech company Inostics GmbH with more than 200 guests from the research community, medicine and industry on Sunday in Hamburg, Germany.
Senator Dr. Herlind Gundelach, Ministry of Science and Research, spoke of the important role the work done at Inostics [...]
